Eli Lilly announced positive Phase 3 results for Retevmo (selpercatinib) in treating RET fusion-positive early-stage non-small cell lung cancer, with the drug demonstrating a substantial reduction in disease recurrence or death risk. The LIBRETTO-432 trial enrolled 151 patients and achieved a highly statistically significant improvement in event-free survival, marking a meaningful advancement in adjuvant cancer therapy for this patient population.
The trial maintained a consistent safety profile throughout the study period, supporting the drug's tolerability in early-stage treatment settings. These results expand Retevmo's clinical utility beyond advanced-stage disease, where the selective RET inhibitor has already demonstrated efficacy in treating RET-driven cancers.
The positive data may strengthen Eli Lilly's position in the precision oncology market, particularly for patients with RET alterations who have limited treatment options. The company is expected to pursue regulatory approval for the adjuvant indication, potentially broadening Retevmo's addressable patient population in lung cancer treatment.